

# Disclosure Statements

**2019 UCI Health Neuroscience Symposium**  
Saturday September 21, 2019

UCI OCME requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of a commercial entity, and promote improvements or quality in healthcare. It is the policy of the UCI Office of Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty participating in UCI sponsored CME programs are expected to disclose to the activity participants any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the activity content. The intent of this policy is identifying potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. It remains for the participants to determine whether the speaker's outside interests reflect a possible bias in either the exposition or the conclusions presented.

All those in control of content have no relevant financial relationships to disclose except the following:

Speaker/ Planner Name	Name of Commercial Interest	Nature of Relevant Relationship	Conflict Resolution Method
Daniela A Bota M.D., Ph.D.	Novocure	Speakers Bureau	Presenters/Authors: I will submit my presentation for peer review PRIOR to the activity and will make content adjustments as appropriate.
Ardith Courtney DO	Teva, Sanofi-Genzyme , Biogen Idec , Genentech	Speakers Bureau, Consultant, Grants/Research Support	Presenters/Authors: I will submit my presentation for peer review PRIOR to the activity and will make content adjustments as appropriate.
Jay Han MD	Sanofi, Bioniks	Speakers Bureau, Consultant	Presenters/Authors: I will submit my presentation for peer review PRIOR to the activity and will make content adjustments as appropriate.

# Disclosure Statements

Speaker/ Planner Name	Name of Commercial Interest	Nature of Relevant Relationship	Conflict Resolution Method
Frank P.K. Hsu MD, PhD	Koh Young America, Inc. , Integra LifeSciences Corporation	Consultant	Presenters/Authors: I will submit my presentation for peer review PRIOR to the activity and will make content adjustments as appropriate., Planners: I will submit the program's curriculum in advance for peer review, and will recuse myself from participating in the planning of any content related to my disclosure information.
Tahseen Mozaffar MD	aTyr Pharma, Ultragenyx, Alexion, Amicus, Sarepta, MT Pharma, Genzyme, Alexion, Amicus, aTyr, Biogen idec, Genzyme, Grifols, Idera, Ionis Pharmaceuticals, Ultragenyx	Advisor or Review Panel Member, Honorarium Recipient, Speakers Bureau, Grants/Research Support	Planners: I will submit the program's curriculum in advance for peer review, and will recuse myself from participating in the planning of any content related to my disclosure information.
Bi-Ying Yeh MD	Cortexyme, Inc	Stock Shareholder (excluding mutual funds)	Presenters/Authors: I will submit my presentation for peer review PRIOR to the activity and will make content adjustments as appropriate.